| US 7,541,344 B2 | ||
| Modulation of survivin expression | ||
| Balkrishen Bhat, Carlsbad, Calif. (US); Bharvin Kumar Patel, Westfield, Ind. (US); and Eric Swayze, Carlsbad, Calif. (US) | ||
| Assigned to Eli Lilly and Company, Indianapolis, Ind. (US); and ISIS Pharmaceuticals, Inc., Carlsbad, Calif. (US) | ||
| Appl. No. 10/559,636 PCT Filed Jun. 03, 2004, PCT No. PCT/US2004/017490 § 371(c)(1), (2), (4) Date Feb. 21, 2007, PCT Pub. No. WO2005/002507, PCT Pub. Date Jan. 13, 2005. |
||
| Claims priority of provisional application 60/475324, filed on Jun. 03, 2003. | ||
| Prior Publication US 2007/0161547 A1, Jul. 12, 2007 | ||
| Int. Cl. A61K 31/70 (2006.01); C07H 21/04 (2006.01); C07H 21/02 (2006.01); C12Q 1/68 (2006.01); C12N 5/00 (2006.01) | ||
| U.S. Cl. 514—44 [435/6; 435/375; 435/377; 536/23.1; 536/24.1; 536/24.5] | 24 Claims |
| 1. A compound comprising a chemically modified or unmodified double-stranded nucleic acid compound 19-23 nucleotides in length,
wherein a first strand of said compound has at least 19 contiguous nucleotides of nucleotide sequence SEQ ID NO: 81, and
wherein a second strand of said compound is 100% complementary to said first strand.
|